UK Medical Device Regulation: UKCA, CE Recognition and MHRA Registration Guide

The United Kingdom is one of the first markets many manufacturers add after the EU, and it is also one of the most changeable. Since Brexit, Great Britain has run its own medical device regime alongside the EU one, and the rules for CE-marked products have moved several times. In October 2026 the UK government confirmed that it intends to recognise CE-marked devices indefinitely. This guide explains what that means, how the UKCA route works, what the MHRA expects from registration and post-market surveillance, and how to plan UK access without duplicating work.

Great Britain and Northern Ireland are different

Start with geography, because it decides which rules apply.

• Great Britain (England, Scotland and Wales): devices are regulated under the UK Medical Devices Regulations 2002 (as amended), enforced by the MHRA.
• Northern Ireland: the EU MDR and IVDR continue to apply under the Windsor Framework arrangements, so EU-style conformity assessment and CE marking remain the main route. A UKNI mark is used where a UK body carried out conformity assessment.

A device that is fully compliant with the EU MDR can therefore serve Northern Ireland directly, while Great Britain has its own set of choices.

The routes to the Great Britain market

Route	What it means	Status in 2026
UKCA marking	Conformity assessment against UK requirements, with a UK Approved Body for devices that need third-party assessment	Available and continuing as the domestic route
CE marking (recognition)	Devices certified under the EU rules continue to be accepted on the GB market	Government confirmed on 21 October 2026 that it intends to recognise EU MDR and IVDR devices indefinitely
International reliance	A route for devices already authorised by comparable regulators	Being developed. Draft 2026 regulations name the US, Canada and Australia, and the CE-recognition decision is handled separately

What changed in 2026

Earlier rules allowed CE-marked devices on the GB market only until set dates, with 30 June 2030 the limit for devices certified under the EU MDR and IVDR. The MHRA consulted in early 2026 on indefinite recognition, and the government’s response on 21 October 2026 confirmed that it intends to recognise EU MDR and IVDR devices indefinitely. The MHRA says more than 90% of devices registered for use in Great Britain carry a CE mark, and the UKCA route stays open alongside CE recognition.

Two cautions apply. First, an announcement of intent is not the same as final legislation, so check the current legal text before you rely on a date or a scope. Second, classification can differ between the UK and the EU. The consultation noted that some self-declared Class I devices would sit in a higher class under the UK rules, which can change which route is open to them.

What every manufacturer must do to sell in Great Britain

1. Classify the device under the UK rules, which resemble the EU rules but are not identical to the EU MDR. Use our overview of device classification as the starting point and then check the UK specifics.
2. Appoint a UK Responsible Person (UKRP) if you are based outside the UK. The UKRP takes defined responsibilities, such as registering the device and acting as a contact point for the MHRA. This is comparable to, but separate from, an EU authorised representative; see our guide to EU MDR economic operators for the EU side.
3. Register the device and the manufacturer with the MHRA before placing the device on the market. Registration is required across all device classes.
4. Complete conformity assessment through the route you have chosen (UKCA with an Approved Body where needed, or CE recognition for an EU-certified device) and keep the technical documentation and declaration of conformity current.
5. Mark and label the device correctly for the route, including the UKCA or CE mark as applicable and the details of the UKRP where required.
6. Run post-market surveillance and vigilance that meets UK rules, described below.

Post-market surveillance in Great Britain

The UK introduced stronger post-market surveillance requirements, which came into force in June 2025. In broad terms, manufacturers must have a PMS system proportionate to the risk class of the device, collect and review real-world data, and produce periodic safety information. Serious incidents must be reported to the MHRA within defined timelines, and trend reporting expectations apply.

If you already operate a PMS system for the EU, most of it carries over, but you should map the differences in reporting timelines, report content and the party who files. Our guide to post-market surveillance explains the EU building blocks, and the page on recalls and field safety corrective actions covers how vigilance feeds field actions.

MDSAP and the UK

The MHRA is an official observer in the Medical Device Single Audit Program. That signals interest in using audit outcomes, but it does not mean an MDSAP certificate replaces UK conformity assessment. Treat MDSAP as useful quality system evidence and plan for UK-specific requirements separately. For background on the program, read ISO 13485 and MDSAP audit readiness.

A practical UK access plan

1. Decide whether CE recognition or UKCA is the better route. If you hold or are pursuing EU MDR certification, CE recognition usually avoids duplicate assessment. UKCA can make sense if you do not plan to certify in the EU, or if classification differences push the device out of the recognition route.
2. Check classification early. A device that is a lower class in the EU than in Great Britain may need a different route.
3. Choose and contract the UKRP and agree who holds the registration data and the technical file access.
4. Update labels and instructions for UK addresses, UKRP details and any required marking, and put them under change control.
5. Align vigilance procedures so one complaint triggers the right report in each region on the right clock.
6. Monitor legislation. Subscribe to MHRA updates, because the final recognition and reliance rules are still being turned into law.

Common mistakes

• Treating Great Britain and Northern Ireland as one market.
• Relying on a news headline about CE recognition instead of the legal text that applies on the day of placing on the market.
• Forgetting that UKCA and CE markings, labels and declarations of conformity are not interchangeable.
• Appointing a UKRP without a clear agreement on responsibilities and document access.
• Using the EU incident reporting process unchanged, without checking UK timelines and the reporting channel.

Frequently asked questions

Is the CE mark accepted in the UK in 2026?

Yes, for Great Britain, CE-marked devices that meet the applicable EU requirements continue to be accepted, and in October 2026 the government confirmed it intends to recognise EU MDR and IVDR devices indefinitely. Confirm the legislation in force when you place a device on the market, and note that Northern Ireland follows the EU rules.

Do I still need UKCA marking?

Not if a CE-marked device qualifies for recognition on your route. UKCA remains available, and it may be needed where a device is not eligible for recognition, for example because of classification differences.

Do I need a UK Responsible Person?

If you are a manufacturer outside the UK and want to place a device on the Great Britain market, you generally need a UK Responsible Person. Check the current MHRA guidance for your device type.

Does FDA clearance help in the UK?

Draft regulations describe an international reliance route that names the US among comparable regulators, so FDA authorisation is expected to become valuable evidence. Until that route is final, check what the MHRA currently accepts.

Rules for UK recognition and reliance are still moving. This article reflects public information available in November 2026 and is for training purposes. Confirm current requirements with the MHRA and your regulatory advisers.

Related reading

• Global market access beyond the US and EU: how to choose and sequence your next markets.
• EU medical device regulations (MDR and IVDR): the CE route that the UK now plans to recognise.
• EU MDR economic operators: authorised representatives, importers and distributors.
• Post-market surveillance: PMS plan, PSUR and vigilance.
• Health Canada licensing: another reliance-friendly market.

Talk to the AptSkill team

Need help choosing between UKCA and CE recognition, or building a UK-ready quality and regulatory plan? Send us your role and goal.